Replies to post #122719 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Evaluate, let me first ask you this.

If mPFS blended for the DCVax-L trial is somewhere between 16.0 to 20 months, do you see the primary endpoint having more or less chance of succeeding?

If mOS blended for the DCVax-L trial is somewhere between 26.0 and 34.0 months, do you see the secondary endpoint having more or less chance of succeeding?

If the long tail survival (four years or more) for DCVax-L is above 29%, and if psPD 32 (24/8) arm merger into the 331 trial increases that to almost 36% for the DCVax-L arm, would you see the Phase III trial as more likely or less likely to succeed?